KAPOSI'S SARCOMA: CHEMOTHERAPY NLM AIDSLINE Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


KAPOSI'S SARCOMA: CHEMOTHERAPY

Kaposi's Sarcoma: Pathophysiology and Clinical Management. Ziegler JL, Dorfman RF, eds. New York, Marcel Dekker, p. 249-59, 1988.. Unique Identifier : AIDSLINE ICDB/89650418
Volberding PA; Sch. of Medicine, Univ. of California, San Francisco, CA

Abstract: The background of chemotherapy in non-AIDS-related Kaposi's sarcoma (KS) is summarized, agents that have been used in patients (pts) with AIDS are discussed, and management guidelines are offered. The following therapeutic agents are discussed: vinblastine, vincristine, etoposide (VP-16), alternating vinblastine and vincristine, combination chemotherapy, alpha-interferon (IFN), and miscellaneous agents. Guidelines for therapy in AIDS-related KS are as follows: (1) for minimal tumor extent with slow progression and favorable prognostic factors--no treatment first, then vinblastine-vincristine or alpha-IFN as a second option or, for pts with unfavorable prognostic factors, vinblastine-vincristine or alpha-IFN first and no immediate treatment as a second option; (2) for extensive disease with rapid growth and favorable prognostic factors--etoposide, Adriamycin, or vinca alkaloids as a first option and alpha-IFN as a second option or, for pts with unfavorable prognostic factors, etoposide or Adriamycin first and vinca alkaloids second; and (3) for pts with locally symptomatic lesions--radiation therapy. (31 Refs)
Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS Antineoplastic Agents/*THERAPEUTIC USE Antineoplastic Agents, Combined/THERAPEUTIC USE Drug Administration Schedule Etoposide/ADMINISTRATION & DOSAGE Human Interferon Type I/THERAPEUTIC USE Sarcoma, Kaposi's/*DRUG THERAPY/THERAPY Skin Neoplasms/*DRUG THERAPY/THERAPY Vinblastine/ADMINISTRATION & DOSAGE Vincristine/ADMINISTRATION & DOSAGE MONOGRAPH REVIEW REVIEW, TUTORIAL

KWDacquiredimmunodeficiencysyndrome/complicationsantineoplasticagents/KWDtherapeuticuseantineoplasticagents,combined/therapeuticusedrugadministrationscheduleetoposide/administration&dosagehumaninterferontypei/therapeuticusesarcoma,kaposi's/KWDdrugtherapy/therapyskinneoplasms/KWDdrugtherapy/therapyvinblastine/administration&dosagevincristine/administration&dosagemonographreviewreview,tutorial
890430
M8940673

Copyright © 1989 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .